Prenatal exposure to arecoline (areca nut alkaloid) and birth outcomes

O Garcia-Algar, O Vall, F Alameda, C Puig, M Pellegrini, R Pacifici, S Pichini


The betel nut is commonly used as a drug by Asian populations. A high prevalence of adverse pregnancy outcomes has been reported in women who chewed betel quid during gestation. The hypothesis that chronic exposure of the fetus to arecoline (the principal alkaloid of the areca nut) is the cause was investigated in a clinical observational study on six newborns from Asian mothers who chewed betel nut during pregnancy.

Some authors have reported a significantly higher prevalence of adverse pregnancy outcomes, including spontaneous abortion, low birth weight, and preterm birth, among women who chewed betel quid during gestation than in non-consumers. However, none hypothesised chronic exposure of the fetus to arecoline (the principal alkaloid of the areca nut) as a possible mechanism.

To investigate if chronic exposure to arecoline can lead to adverse birth outcomes, some not yet recognised, we set up a clinical observational study on six newborns from Asian mothers who admitted to betel nut consumption during pregnancy.

Pregnant women, recruited within the framework of the Meconium Project at the Hospital del Mar in Barcelona, Spain, had a complete clinical examination and were interviewed about their use of cigarettes and illicit drugs during pregnancy. At the time of delivery, newborn somatometry and clinical signs were recorded.

Table 1 Results of the clinical observational study on six newborns from mothers who chewed betel nut during pregnancy

<table>
<thead>
<tr>
<th>Case No</th>
<th>Birth weight (g)</th>
<th>Crown-heel length (cm)</th>
<th>Cranial perimeter (cm)</th>
<th>Gestation (weeks)</th>
<th>Clinical signs</th>
<th>Placental morphology</th>
<th>Meconium (µg/g)</th>
<th>Placenta</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3450</td>
<td>51</td>
<td>34</td>
<td>41</td>
<td>None</td>
<td>577 g; macro and micro normal</td>
<td>0.008</td>
<td>ND</td>
</tr>
<tr>
<td>2</td>
<td>3090</td>
<td>49</td>
<td>34</td>
<td>38</td>
<td>Neonatal withdrawal syndrome treated with 5 mg/kg phenobarbital for 3 subsequent days</td>
<td>655 g; macro normal, micro acute focal chorioamnionitis</td>
<td>NA</td>
<td>0.012</td>
</tr>
<tr>
<td>3</td>
<td>2430</td>
<td>47</td>
<td>33</td>
<td>41</td>
<td>Low birth weight, low intrauterine growth, small for gestational age, hyporeflexia, hypotonia</td>
<td>435 g; macro normal, micro acute focal chorioamnionitis, reduced vascular diameter</td>
<td>0.006</td>
<td>0.009</td>
</tr>
<tr>
<td>4</td>
<td>3260</td>
<td>49</td>
<td>34</td>
<td>39.6</td>
<td>None</td>
<td>548 g; macro and micro normal</td>
<td>0.022</td>
<td>0.013</td>
</tr>
<tr>
<td>5</td>
<td>2865</td>
<td>48</td>
<td>32</td>
<td>38.3</td>
<td>None</td>
<td>498 g; macro and micro normal</td>
<td>NA</td>
<td>0.015</td>
</tr>
<tr>
<td>6</td>
<td>3575</td>
<td>52</td>
<td>35</td>
<td>40.4</td>
<td>None</td>
<td>468 g; macro and micro normal</td>
<td>0.017</td>
<td>0.014</td>
</tr>
</tbody>
</table>

NA, Not available; ND, not detected.

Arecoline concentration was determined in meconium to assess fetal exposure to this alkaloid and in the placenta, to be associated with studies on the morphology of placental tissue from consumer mothers. Meconium samples were also analysed for the principal drugs of abuse and cotinine to exclude prenatal exposure to drugs other than arecoline.

Two adverse birth outcomes were observed in the six exposed newborns (table 1). In both cases, risk factors other than chronic betel quid consumption could be excluded from maternal records, and neonatal brain ultrasonography was inconclusive. Focal inflammatory changes in the amniochorial membranes were observed in the placentas in both cases (table 1), and in case 3 a decreased median diameter of the vessels in both maternal and fetal surface villi was also observed.

Although the effects of betel chewing are well established in adults, teratogenic effects of prenatal betel exposure have only been shown in animal models, and data for humans are scant.

In our study, arecoline was determined in biological matrices accounting for acute and chronic fetal exposure to this substance, exposure associated with placental abnormalities, and neonatal outcomes, including neonatal withdrawal syndrome, as an exceptional adverse birth outcome not yet described in the literature. The recognised biochemical effects of arecoline on the autonomic nervous system and the recognised embryotoxicity in animals, together with our findings, allowed us to hypothesise a number of effects on the fetus related to abnormalities of the fetoplacental circulation, similar to those observed with nicotine or cocaine.

These preliminary findings did not allow any definitive conclusion on the correlation between fetal exposure to arecoline and clinical outcomes. Information on differences in patterns of drug use (amount, timing, and duration of drug exposure), related to clinical outcomes, was not...
available from the study questionnaire, nor could it be
deduced from the arecoline concentration in the meconium,
as is the case for other illicit drugs. Furthermore, as this was
the first time that arecoline had been detected in meconium
and placenta, no concentration ranges were available, which
may have allowed speculations on amounts.

Our observations require support from further investiga-
tions, addressing the above issues and including an extended
follow up of prenatally exposed newborns in areas with a
high prevalence of betel nut consumption.

Authors’ affiliations
O García-Algar, O Vall, C Puig, Paediatric Service, Unitat de Recerca
Infància i Entorn (URIE), Hospital del Mar, Barcelona, Spain and
Departament de Pediatric, Ginecologia i Obstetricia, i Medicina
Preventiva, Universitat Autònoma, Barcelona, Spain
F Alameda, Pathology Service, Hospital del Mar
M Pellegrini, R Pacifici, S Pichini, Drug Research and Evaluation
Department, Istituto Superiore di Sanità, Rome, Italy

This study was supported by “Area Progetto Droga” (Convenzione
513A/4) from Istituto Superiore di Sanità, Roma, Italy.

Competing interests: none declared

Correspondence to: Dr García-Algar, Pediatric Service, Hospital del
Mar, Paseo Marítimo 25–29, 08003 Barcelona, Spain;
OGarciaA@imas.imim.es

Accepted 13 October 2004

REFERENCES
1 Gupta PC, Warnakulasuriya S. Global epidemiology of areca nut usage.
2 Yang MS, Chung TC, Yang MJ, et al. Betel quid chewing and risk of adverse
birth outcomes among aborigines in eastern Taiwan. J Toxicol Environ
3 Pichini S, Pellegrini M, Pacifici R, et al. Quantification of arecoline (Arena Nut
alkaloid) in neonatal biological matrices by high-performance liquid
chromatography/electrospray quadrupole mass spectrometry. Rapid
of the placenta: developed by the Placental Pathology Practice Guideline
Development Task Force of the College of American Pathologists. Arch Pathol
Lab Med 1997;121:449–76.
5 Sinha A, Rao AR. Embryotoxicity of betel nuts in mice. Toxicology
Prenatal exposure to arecoline (areca nut alkaloid) and birth outcomes

O García-Algar, O Vall, F Alameda, C Puig, M Pellegrini, R Pacifici and S Pichini

Arch Dis Child Fetal Neonatal Ed 2005 90: F276-FF277
doi: 10.1136/adc.2004.061325

Updated information and services can be found at:
http://fn.bmj.com/content/90/3/F276

These include:

References
This article cites 5 articles, 0 of which you can access for free at:
http://fn.bmj.com/content/90/3/F276#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Pregnancy (1521)
Reproductive medicine (1433)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/